Chemomab Therapeutics Ltd. announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions. He will be responsible for spearheading the corporate development function, including guiding company strategy, tracking competitive and market developments, and identifying, negotiating and managing partnerships and potential acquisitions.

Dr. Jones most recently served as Vice President Clinical Discovery and Development at Nasdaq-listed Finch Therapeutics, where he contributed to a successful IPO and helped oversee the clinical development of novel therapeutics for treating inflammatory bowel disease and cancer. Prior to Finch, Dr. Jones served as Vice President of Translational and Clinical Development at Nasdaq-listed Biora Therapeutics, formerly known as Progenity, developing clinical program strategy and overseeing development of its advanced technologies for targeted drug delivery to the GI tract and needle-free delivery of biotherapeutics. Previously, he served as Vice President, Innovation and Clinical Translational Development, helping to formulate and implement a strategic roadmap encompassing all aspects of the business while contributing to both a $125 million venture financing and the company's subsequent IPO.

Earlier, Dr. Jones helped establish and then managed the successful trade sale of the technology platform and assets of Interface Biosciences. Early in his career, Dr. Jones founded Micropharma, where he served as Head of Research & Development. He directed the development of an innovative bioinformatics platform and multiple clinical programs, concluded major licensing agreements with global industry partners, raised a financing round that included non-dilutive, partnering and venture capital, and managed the company's subsequent acquisition at a value ultimately exceeding half a billion dollars.

Dr. Jones is the author or co-author of numerous scientific abstracts, proceedings and publications and an inventor on almost 200 filed or granted patents. He received his MD and PhD degrees, and a masters in biomedical engineering and a bachelor of science degree, from McGill University in Canada.